FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053251658> ?p ?o ?g. }

• W2053251658 endingPage "353" @default.
• W2053251658 startingPage "353" @default.
• W2053251658 abstract "Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability Javier Arrieta,1 Iñigo Moina,1 José Molina,2 Isabel Gallardo,3 María Luisa Muñiz,4 Carmen Robledo,5 Oscar García,5 Fernando Vidaur,6 Rosa Inés Muñoz,3 Izaskun Iribar,7 Román Aguirre,7 Antonio Maza8 1Hospital de Basurto, Bilbao, 2Hospital de Donostia, Donostia-San Sebastián, 3Hospital de Galdakao-Usansolo, Galdakao, 4Hospital de Cruces, Baracaldo, 5Hospital de Santiago, Vitoria-Gasteiz, 6Policlínica de Guipúzcoa, Donostia-San Sebastián, 7Hemobesa Clinica Virgen Blanca, Bilbao, 8Dialbilbo, Bilbao, Spain Aim: The objective of the study reported here was to describe dose equivalence and hemoglobin (Hb) stability in a cohort of unselected hemodialysis patients who were switched simultaneously from epoetin alfa to darbepoetin alfa. Methods: This was a multicenter, observational, retrospective study in patients aged $18 years who switched from intravenous (IV) epoetin alfa to IV darbepoetin alfa in October 2007 (Month 0) and continued on hemodialysis for at least 24 months. The dose was adjusted to maintain Hb within 1.0 g/dL of baseline. Results: We included 125 patients (59.7% male, mean [standard deviation (SD)] age 70.4 [13.4] years). No significant changes were observed in Hb levels (mean [SD] 11.9 [1.3] g/dL, 12.0 [1.5], 12.0 [1.5], and 12.0 [1.7] at Months −12, 0, 12 and 24, respectively, P=0.409). After conversion, the erythropoiesis-stimulating agent (ESA) dose decreased significantly (P<0.0001), with an annual mean of 174.7 (88.7) international units (IU)/kg/week for epoetin versus 95.7 (43.4) (first year) and 91.4 (42.7) IU/kg/week (second year) for darbepoetin (65% and 64% reduction, respectively). The ESA resistance index decreased from 15.1 (8.5) IU/kg/week/g/dL with epoetin to 8.1 (3.9) (first year) and 7.9 (4.0) (second year) with darbepoetin (P<0.0001). The conversion rate was 354:1 in patients requiring high (>200 IU/kg/week) doses of epoetin and 291:1 in patients requiring low doses. Conclusion: In patients on hemodialysis receiving ESAs, conversion from epoetin alfa to darbepoetin alfa was associated with an approximate and persistent reduction of 65% of the required dose. To maintain Hb stability, a conversion rate of 300:1 seems to be appropriate for most patients receiving low doses of epoetin alfa (≤200 IU/kg/week), while 350:1 would be better for patients receiving higher doses. Keywords: chronic kidney disease, darbepoetin alfa, dose equivalence, epoetin alfa, hemodialysis, hemoglobin" @default.
• W2053251658 created "2016-06-24" @default.
• W2053251658 creator A5002176767 @default.
• W2053251658 creator A5020191517 @default.
• W2053251658 creator A5024437283 @default.
• W2053251658 creator A5034253918 @default.
• W2053251658 creator A5040607779 @default.
• W2053251658 creator A5044835141 @default.
• W2053251658 creator A5048121933 @default.
• W2053251658 creator A5058414697 @default.
• W2053251658 creator A5060479452 @default.
• W2053251658 creator A5067661373 @default.
• W2053251658 creator A5087395970 @default.
• W2053251658 creator A5091565827 @default.
• W2053251658 date "2014-10-01" @default.
• W2053251658 modified "2023-10-10" @default.
• W2053251658 title "Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability" @default.
• W2053251658 cites W1715452167 @default.
• W2053251658 cites W1963516841 @default.
• W2053251658 cites W1964706798 @default.
• W2053251658 cites W1970157737 @default.
• W2053251658 cites W1999459819 @default.
• W2053251658 cites W2008263479 @default.
• W2053251658 cites W2049843297 @default.
• W2053251658 cites W2056990990 @default.
• W2053251658 cites W2070793978 @default.
• W2053251658 cites W2077030445 @default.
• W2053251658 cites W2077891756 @default.
• W2053251658 cites W2082381402 @default.
• W2053251658 cites W2097391350 @default.
• W2053251658 cites W2097397503 @default.
• W2053251658 cites W2106959466 @default.
• W2053251658 cites W2108511043 @default.
• W2053251658 cites W2114505956 @default.
• W2053251658 cites W2114572286 @default.
• W2053251658 cites W2135819931 @default.
• W2053251658 cites W2143201063 @default.
• W2053251658 cites W2148520689 @default.
• W2053251658 cites W2153229011 @default.
• W2053251658 cites W2153339950 @default.
• W2053251658 cites W2166142160 @default.
• W2053251658 cites W2169777612 @default.
• W2053251658 cites W2394917518 @default.
• W2053251658 cites W2398178439 @default.
• W2053251658 cites W2406779310 @default.
• W2053251658 cites W2414915186 @default.
• W2053251658 cites W272815265 @default.
• W2053251658 cites W3189724067 @default.
• W2053251658 cites W59193685 @default.
• W2053251658 doi "https://doi.org/10.2147/ijnrd.s61895" @default.
• W2053251658 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4199978" @default.
• W2053251658 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25336984" @default.
• W2053251658 hasPublicationYear "2014" @default.
• W2053251658 type Work @default.
• W2053251658 sameAs 2053251658 @default.
• W2053251658 citedByCount "2" @default.
• W2053251658 countsByYear W20532516582022 @default.
• W2053251658 crossrefType "journal-article" @default.
• W2053251658 hasAuthorship W2053251658A5002176767 @default.
• W2053251658 hasAuthorship W2053251658A5020191517 @default.
• W2053251658 hasAuthorship W2053251658A5024437283 @default.
• W2053251658 hasAuthorship W2053251658A5034253918 @default.
• W2053251658 hasAuthorship W2053251658A5040607779 @default.
• W2053251658 hasAuthorship W2053251658A5044835141 @default.
• W2053251658 hasAuthorship W2053251658A5048121933 @default.
• W2053251658 hasAuthorship W2053251658A5058414697 @default.
• W2053251658 hasAuthorship W2053251658A5060479452 @default.
• W2053251658 hasAuthorship W2053251658A5067661373 @default.
• W2053251658 hasAuthorship W2053251658A5087395970 @default.
• W2053251658 hasAuthorship W2053251658A5091565827 @default.
• W2053251658 hasBestOaLocation W20532516581 @default.
• W2053251658 hasConcept C126322002 @default.
• W2053251658 hasConcept C2778063415 @default.
• W2053251658 hasConcept C2778917026 @default.
• W2053251658 hasConcept C2781404941 @default.
• W2053251658 hasConcept C71924100 @default.
• W2053251658 hasConcept C90924648 @default.
• W2053251658 hasConceptScore W2053251658C126322002 @default.
• W2053251658 hasConceptScore W2053251658C2778063415 @default.
• W2053251658 hasConceptScore W2053251658C2778917026 @default.
• W2053251658 hasConceptScore W2053251658C2781404941 @default.
• W2053251658 hasConceptScore W2053251658C71924100 @default.
• W2053251658 hasConceptScore W2053251658C90924648 @default.
• W2053251658 hasLocation W20532516581 @default.
• W2053251658 hasLocation W20532516582 @default.
• W2053251658 hasLocation W20532516583 @default.
• W2053251658 hasLocation W20532516584 @default.
• W2053251658 hasOpenAccess W2053251658 @default.
• W2053251658 hasPrimaryLocation W20532516581 @default.
• W2053251658 hasRelatedWork W113810927 @default.
• W2053251658 hasRelatedWork W1511881851 @default.
• W2053251658 hasRelatedWork W1977146315 @default.
• W2053251658 hasRelatedWork W1984576678 @default.
• W2053251658 hasRelatedWork W2025499134 @default.
• W2053251658 hasRelatedWork W2031196132 @default.
• W2053251658 hasRelatedWork W2243730984 @default.
• W2053251658 hasRelatedWork W2356500668 @default.
• W2053251658 hasRelatedWork W2400333011 @default.

• next